Daewoong pharmaceutical Co.,Ltd (069620.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1635.2B	1570.9B	1422.7B	1375.3B	1280.1B
Cost of Revenue	791.6B	758.0B	688.5B	688.2B	641.1B
Gross Profit	843.6B	812.9B	734.2B	687.1B	639.0B
Operating Expenses
R&D Expense	193.3B	180.3B	171.3B	171.6B	163.6B
SG&A Expense	344.8B	294.9B	268.2B	383.4B	245.4B
General & Admin Expense	64.9B	28.3B	22.3B	21.2B	20.4B
Selling & Marketing Expense	280.0B	266.6B	245.9B	235.8B	225.0B
Other Expenses	255.0B	142.1B	146.7B	10.6B	134.1B
Total Operating Expenses	653.1B	617.3B	586.2B	565.6B	543.2B
Cost and Expenses	1444.7B	1374.1B	1274.7B	1254.2B	1184.3B
Operating Income (EBIT)	190.5B	195.5B	147.9B	121.1B	95.8B
Non-Operating
Interest Income	3.5B	2.6B	5.1B	1.1B	4.1B
Interest Expense	14.6B	12.5B	7.0B	13.1B	8.4B
Net Interest Income	(11.2B)	(9.9B)	(1.9B)	(12.0B)	(4.3B)
Other Non-Op Income/Expense	(10.9B)	(3.7B)	(91.4B)	881.5M	(57.5B)
Non-Operating Income (excl Interest)	(29.2B)	—	84.4B	—	48.7B
EBT (Pre-Tax Income)	179.6B	191.8B	56.6B	122.0B	38.3B
Income Tax Expense	1.1B	(1.1B)	33.2B	2.0B	(833.5M)
Bottom Line
Net Income	195.5B	195.9B	24.7B	121.7B	42.2B
Earnings from Cont. Ops	178.4B	192.9B	23.3B	120.0B	39.2B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	195.5B	195.9B	24.7B	121.7B	42.2B
Per Share
Basic EPS	₩16,989	₩17,021	₩2,150	₩10,656	₩3,816
Diluted EPS	₩16,989	₩17,021	₩2,150	₩10,656	₩3,816
Revenue Per Share	₩141,124	₩135,573	₩123,647	₩120,389	₩115,647
Shares
Basic Shares Outstanding	11.6M	11.6M	11.5M	11.4M	11.1M
Diluted Shares Outstanding	11.6M	11.6M	11.5M	11.4M	11.1M
Profitability Metrics
EBITDA	255.6B	245.8B	112.5B	164.9B	85.1B
D&A	66.4B	50.3B	49.0B	43.8B	38.0B
EBIT	189.2B	195.5B	63.5B	121.1B	47.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026